key: cord-0920039-18x2p7cz authors: Mutnal, Manohar B.; Johnson, Shelby; Mohamed, Nada; Abddelgader, Rasha; Morales, Linden; Volz, Marcus; Walker, Kimberly; Arroliga, Alejandro C.; Rao, Arundhati title: Surveillance genome sequencing reveals multiple SARS‐CoV‐2 variants circulating in central Texas, USA, with a predominance of delta variant and review of vaccine breakthrough cases date: 2021-10-07 journal: J Med Virol DOI: 10.1002/jmv.27373 sha: 6fbf68af03b166ba524117b592407e68b9b3ed9d doc_id: 920039 cord_uid: 18x2p7cz As surges in the COVID‐19 pandemic have continued worldwide, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has mutated, spawning several new variants, and impacting, to various degrees, transmission, disease severity, diagnostics, therapeutics, and natural and vaccine‐induced immunity. Baylor Scott & White Health has implemented, along with laboratory diagnosis, SARS‐CoV‐2 sequencing to identify variants in its geographical service area. We analyzed virus sequencing results of specimens collected across Central Texas and found dramatic changes in variant distribution in the first half of 2021. The alpha variant (B 1.1.7) became predominant at week 13 and continued dominance until week 25. A growth rate of 1.20 (R (2) = 0.92) for the first 15 weeks was noted and this growth gradually declined to −0.55 (R (2) = 0.99) for the final 13 weeks. Currently, B.1.1.7 is being displaced with B.1.617.2 at a 0.58 growth rate (R (2) = 0.97). We also investigated vaccine breakthrough cases (VBCs) within our healthcare system and present clinical data on 28 symptomatic patients. RNA viruses exist as a swarm or "quasispecies" of genome sequences around a core consensus sequence. 7 Under conditions of selection, such as those imposed by neutralizing antibodies or drugs, variants of the swarm can escape genetically and become resistant. To date, 4150 mutations have been identified in the S gene of SARS-CoV-2 isolated from humans (CoV-GLUE, 2021; GISAID, 2021). These mutations give rise to 1246 amino acid changes including 187 substitutions in the receptor-binding domain (RBD). 8 The abundance of many variants in the human population suggests specimens. The reports generated were not released to patients' electronic health records (EHR) but were provided to public health officials for necessary interventions when a variant of concern (VOC) or variant of interest (VOI) was identified. Similarly, VBCs were identified and reported according to Centers for Disease Control and Prevention (CDC) definitions. 9 In this report, we present the evolution of SARS-CoV-2 lineages in the Central Texas area, and their association with VBCs, along with a clinical history of those breakthrough cases. In large, randomizedcontrolled trials, each vaccine was found to be safe and efficacious in preventing symptomatic, laboratory-confirmed COVID- 19. 1011 In this report, we present the evolution of SARS-CoV-2 lineages in the limited geography of Central Texas and their association with vaccine breakthrough along with a clinical history of vaccinated patients exposed to variants. Research Institute Institutional Review Board (IRB # 021-144) with a waiver of the requirement of informed consent for the use of residual specimens for sequencing and epidemiological studies. Since the beginning of the pandemic, our laboratory has archived all the positive specimens confirmed by one of the nucleic acid amplification methods that were deployed for the diagnosis of SARS-CoV-2 infections. Since the implementation of sequencing, both retrospective and prospective specimens have been selected for variant identification in our community. The BSWH molecular pathology laboratory has conducted approximately 400 000 tests and SARS-CoV-2 and reported a 10.8% overall positivity rate for the Central Texas geography. These We randomly selected 1% of the positive specimens for sequencing when positivity rates were higher than 5% and all positive specimens when positivity rates were <5%, to identify the variants in circulation. An electronic query was set up in the EHR to identify patients with a COVID-19 vaccination history. If patients were tested multiple times postvaccination, they were distinctly counted, and the first positive was counted for statistical purposes. Retrospective data collection for VBTs was done from the beginning of the year 2021; however, many clinical specimens were not available for sequencing. Among 72 VBTs, we were able to salvage 33 specimens for sequencing. Among the 33 VBTs, we collected clinical data for 28 patients from BSWH, EHR. The remaining five patients may have used the BSWH system for vaccination and testing purposes only and BSWH, EHR did not have any relevant clinical data. In Figure 3 , specimens excluded from sequencing due to unavailability and low virus load have been shown, 39 specimens in total were excluded from sequencing. Nucleic acid was purified from each specimen and subjected to reverse transcription, next-generation sequencing library preparation, sequencing, and data analysis according to the manufacturer's recommendation using two different platforms. Extracted RNA was subject to reverse transcription using the Su-perScript VILO cDNA Synthesis Kit Chef (ThermoFisher Scientific). Library preparation and subsequent templates were performed using the Ampliseq SARS-CoV-2 Research Panel, DL8 kit, and the Ion 510 & Ion 520 & Ion 530 Kit on the Ion Chef. Sequencing was performed on the Ion Torrent S5. Data were manually uploaded to the Next-Clade bioinformatics pipeline for analysis. Epidemiological, demographic, clinical, and laboratory data were extracted from EHR and the laboratory information system. Descriptive analysis was performed to present demographics factors (age, gender, and ethnicity), clinical presentation, clinical outcome, and molecular studies on SARS-CoV-2 specimens. Growth rate statistical analyses were performed in SAS 9.4. All graphs were created in R version 3.5.1. To calculate growth curves, the Verhulst growth model, also known as the logistic growth model, was used to model population growth with constraints. The formula for the Verhulst growth model is: Genome sequencing was introduced to detect SARS-CoV-2 variants from the beginning of the year, 2021. We randomly selected 1% of the positive specimens for sequencing during the initial weeks when positivity rates were higher than 5% and once the overall positivity rate was below 5% all positive specimens were in the pipeline for sequencing to identify the variants in circulation. Data presented in Figure 3 show the weekly distribution of VBCs We performed a review of EHR of patients who were fully vaccinated and experienced vaccine breakthroughs ( Finally, the findings in this report are subject to at least two limitations. First, the number of reported COVID-19 vaccine breakthrough cases is likely a substantial undercount of all SARS-CoV-2 infections among fully vaccinated persons. This study relied on the EHR of patients within our healthcare system and data might not be complete or representative. Many persons with vaccine breakthrough infections, especially those who are asymptomatic or who experience mild illness, might not seek testing. Second, SARS-CoV-2 sequence data are available for only a small proportion of the reported cases. The authors would like to thank Kendall Hammonds for help with statistical analysis and Briget Da Graca for editorial help. The authors declare that there are no conflict of interests. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. Manohar B. Mutnal http://orcid.org/0000-0002-0452-7382 COVID-19 Dashboard The emerging SARS-CoV-2 variants of concern Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19) StatPearls. StatPearls Publishing Vaccine-escape and fast-growing mutations in the United Kingdom, the United States Effectiveness of Covid-19. Vaccines against the B.1.617.2 (Delta) Variant | NEJM Vaccine breakthrough infections with sars-cov-2 variants Mapping the evolutionary potential of RNA viruses Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization Centers for Disease Control and Prevention. Breakthrough Case Investigations and Reporting. 2021. Accessed Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine Rapid displacement of SARS-CoV-2 variant B.1.1.7 by B.1.617.2 and P.1 in the United States Centers for Disease Control and Prevention. 2020. COVID Data Tracker. 2020. Accessed Genomic surveillance for SARS-CoV-2 variants circulating in the United States & Executive Order GA 34: Relating to the opening of Texas in response to the COVID-19 disaster COVID-19 in Texas (Dashboard). 2021. Accessed COVID-19 in Texas -Texas Tests and Hospitals (Dashboard) Rate and risk factors for breakthrough SARS-CoV-2 infection after vaccination Elucidating causes of COVID-19 infection and related deaths after vaccination CDCMMWR. COVID-19 vaccine breakthrough infections reported to CDC-United States Surveillance genome sequencing reveals multiple SARS-CoV-2 variants circulating in central Texas, USA, with a predominance of delta variant and review of vaccine breakthrough cases